Please login to the form below

Not currently logged in
Email:
Password:

Novartis appoints Shaun Coughlin to lead its US biomedical research institute

The renowned academic joins as the pharma firm's global head of cardiovascular and metabolism

Shaun CoughlinNovartis has appointed Shaun Coughlin to head up its biomedical research institute based in Cambridge, Massachusetts, as its new global head of cardiovascular and metabolism.

He joins the pharma giant from the University of California San Francisco’s (UCSF) cardiovascular research centre, where he was previously a director. He has served UCSF for 33 years.

Talmadge King Jr, dean, school of medicine at USFC, said: “We are sad to lose on our most respected leaders, yet profoundly grateful for his decades of service and immeasurable contributions to our mission.

“Dr Coughlin is an outstanding example of the personal qualities that collectively have propelled UCSGF to the top.”

Coughlin is also a member of the National Academy of Scienes, the National Academy of Medicine and the American Academy of Arts & Scienes and has won numerous awards including Brisol-Myers Squibb’s Cardiovascular Research Award.

23rd August 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics